Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma - Kelly, R J; Chung, K; Yu, G (J Immunother Cancer, 2015)
et al.